Natera, Inc. $NTRA Shares Bought by Andra AP fonden

Andra AP fonden grew its stake in Natera, Inc. (NASDAQ:NTRA) by 193.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 82,737 shares of the medical research company’s stock after acquiring an additional 54,537 shares during the quarter. Andra AP fonden’s holdings in Natera were worth $16,547,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Reflection Asset Management acquired a new position in Natera in the 4th quarter valued at about $29,000. Palladiem LLC purchased a new position in Natera in the 4th quarter valued at about $31,000. Horizon Investments LLC acquired a new stake in shares of Natera during the 3rd quarter worth about $32,000. International Assets Investment Management LLC boosted its stake in shares of Natera by 132.9% during the 1st quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock worth $35,000 after purchasing an additional 97 shares during the last quarter. Finally, Bank of Jackson Hole Trust grew its holdings in shares of Natera by 103.8% during the fourth quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock worth $37,000 after buying an additional 83 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on NTRA shares. UBS Group set a $260.00 price objective on shares of Natera in a research note on Wednesday, June 24th. Wall Street Zen downgraded Natera from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. The Goldman Sachs Group initiated coverage on Natera in a research note on Friday, June 5th. They set a “neutral” rating and a $245.00 price target on the stock. BTIG Research set a $275.00 price objective on Natera and gave the stock a “buy” rating in a report on Wednesday, June 24th. Finally, Evercore restated an “outperform” rating and set a $300.00 price objective on shares of Natera in a report on Monday, July 6th. Three analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Natera presently has a consensus rating of “Moderate Buy” and an average price target of $267.83.

Natera Stock Up 1.7%

Shares of NASDAQ NTRA opened at $267.18 on Wednesday. The stock has a market capitalization of $38.26 billion, a PE ratio of -163.91 and a beta of 1.51. The firm has a fifty day moving average of $236.50 and a 200-day moving average of $220.83. Natera, Inc. has a 52-week low of $131.81 and a 52-week high of $288.04.

Insider Transactions at Natera

In other news, Director Gail Boxer Marcus sold 11,000 shares of the business’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $217.21, for a total transaction of $2,389,310.00. Following the completion of the sale, the director owned 6,183 shares in the company, valued at approximately $1,343,009.43. The trade was a 64.02% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Roelof Botha sold 78,000 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $220.31, for a total transaction of $17,184,180.00. Following the sale, the director directly owned 1,076,198 shares of the company’s stock, valued at approximately $237,097,181.38. This trade represents a 6.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 178,872 shares of company stock valued at $39,627,696 in the last ninety days. Company insiders own 5.05% of the company’s stock.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.